We present results of two similarly designed but separate phase II studies, involving single agent lenalidomide (CC-5013, Revlimid ®
Introduction
Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by intense bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis.
1 The molecular pathogenesis of MMM has not been fully characterized despite the recent discovery of an activating JAK2 mutation (JAK2
V617F
) that is found in approximately half of the patients with MMM but also in the majority of those with either polycythemia vera or essential thrombocythemia. 2 Other non-specific genetic markers in MMM include deletions of the long arms of chromosomes 13 and 20 and occasionally that of chromosome 5. 3 Clinical phenotype includes progressive anemia, marked splenomegaly, extramedullary hematopoiesis, and a leukoerythroblastic blood smear. Average life expectancy is estimated at 5-7 years but exceeds 10 years in young patients with good prognostic features. 4 However, quality of life is often compromised by frequent red blood cell transfusions as well as a markedly enlarged spleen that is usually accompanied by both mechanical discomfort and profound constitutional symptoms.
Conventional drug therapy in MMM has not been shown to improve survival and is used for palliative purposes only. In this regard, androgen preparations, corticosteroids, and erythropoietin are often used as first line therapy for alleviation of anemia. 1 Symptomatic splenomegaly is initially treated with hydroxyurea and subsequently with splenectomy. 5 Involved field radiation therapy is most effective for non-hepatosplenic extramedullary hematopoiesis 6 but has limited value in controlling symptomatic enlargement of the spleen and liver. 7, 8 Treatment with allogeneic hematopoietic stem cell transplant, either myeloablative 9 or reduced intensity conditioning, 10 is directed at eradicating the mutant MMM clone. However, this particular treatment modality is risky, in terms of both mortality and morbidity, and may not be applicable to the majority of patients. Therefore, novel therapeutic approaches are urgently needed.
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From There is increasing evidence that bone marrow fibrosis and angiogenesis in MMM are mediated by clonal cell-derived cytokines including transforming growth factor-β (TGF-β), 11 plateletderived growth factor (PDGF), 12 basic fibroblast growth factor (bFGF), 13 and tumor necrosis factor-α (TNF-α). 14 Because of the potent anti-angiogenic 15 as well as cytokine modulating 16 activity of thalidomide, we had previously piloted the specific drug in MMM and subsequently showed a clinically relevant benefit in terms of both anemia and splenomegaly with the respective response rates of 20% and 25%. 17 Encouraged by this experience, we explored the clinical activity of the more potent thalidomide analog, lenalidomide (CC-5013; Revlimid ® ), 18 in 68 symptomatic patients with MMM that were accrued to two separate phase II studies at the Mayo Clinic (n=27) and MD Anderson Cancer
Center (n=41).
Methods
Approval was obtained from the Mayo Clinic and MD Anderson Cancer Center institutional review boards for these studies. Informed consent was provided according to the Declaration of Helsinki. The current communication summarizes the results of two separate phase II studies involving single agent lenalidomide therapy in patients with MMM. The studies were conducted under institutional review board approval and protocol entry criteria for both centers are outlined in Table 1 .
Conventional criteria were used for the diagnosis of MMM including all subtypes; agnogenic (AMM), post-polycythemic (PPMM), and post-thrombocythemic (PTMM) myeloid metaplasia. 19 Patients with acute myelofibrosis or myelodysplastic syndrome with myelofibrosis were not eligible for participation in the current study. Baseline bone marrow histology and cytogenetic studies were performed in all study patients from both treatment centers. In addition, pretreatment (all patients) and posttreatment (major anemia responders) bone marrow microvessel density assessment and JAK2 V617F mutation analysis were performed in patients accrued to the Mayo Clinic study. Pre-treatment JAK2
V617F
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From mutation analysis was performed in 35 patients in the MD Anderson Cancer Center study. Previously published methods were used to grade bone marrow reticulin fibrosis and microvessel density, 20, 21 perform karyotype and fluorescent in situ hybridization (FISH) analysis, 22 and screen for JAK2 V617F mutation. 23, 24 Concurrent therapy with other agents was not allowed in the current study. Response criteria used in the current study are outlined as a footnote accompanying Table 3 . The National
Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) were used to assess drug toxicity. 25 In addition to the combined presentation of overall response information, each one of the two phase II studies was analyzed separately for both response and toxicity data. Where appropriate, statistical analysis was performed by using Stat view software, version 5.01, (SAS, Cary, NC).
Results
Sixty-eight patients with MMM were enrolled in two similarly designed but separate phase II studies at the Mayo Clinic (n=27) and MD Anderson Cancer Center (n=41). Treatment protocols consisted of single agent oral lenalidomide according to the dose and schedule outlined in Table 1 .
Baseline clinical and laboratory characteristics of the study population are outlined in Table 2 .
Response and drug toxicity data from both treatment centers are summarized in Tables 3 and 4, respectively. 
ii. Treatment details and adverse events
All 27 patients were started on a daily dose of 10 mg/day. Two patients received treatment for less than 2 weeks because of cutaneous adverse events. Other drug side effects (Table 4 ) and disease progression were responsible for not completing the first 3 cycles of treatment in an additional 11
patients. Fourteen patients (52%) received 3 to 6 cycles of treatment depending primarily on the absence or presence of response to the first 3 cycles of treatment, respectively (Table 1 ). In addition to the events listed in Table 4 , three patients (one with PTMM and 2 with AMM) experienced marked thrombocytosis (peak platelet count 727-1598 x 10 9 /L) and 2 other patients each displayed erythrocytosis (hemoglobin peak at 19.1 g/dL in a patient with PPMM) or biopsy-proven disseminated extramedullary hematopoiesis (one patient with AMM), all temporally associated with the study drug.
Among the 5 patients who experienced drug-associated dyspnea, pulmonary hypertension was documented in 2 patients. Most adverse events improved upon drug withdrawal and none were directly connected to patient demise. To date, 8 deaths have been reported, all occuring after discontinuation of protocol therapy and most were attributed to progressive disease; 2 patients died of acute leukemia after approximately 14 and 60 weeks from last day of protocol treatment, 4 patients died of progressive disease without leukemic transformation after approximately 3, 4, 24, and 36 weeks from protocol
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From drug discontinuation, 1 patient died of congestive hear failure and renal insufficiency after 3 weeks from drug discontinuation, and 1 patient died of sepsis and renal insufficiency after 24 weeks from drug discontinuation. In addition, one of the patients who died with progressive disease also experienced sepsis and acute respiratory distress syndrome at the time of death.
iii. Response to lenalidomide therapy
The median post-treatment follow up at the time of this writing was 19 months (range 6-20 months) and all patients have either completed or discontinued protocol drug therapy. Individual response rates in anemia, splenomegaly, hypercatabolic symptoms, and serum lactate dehydrogenase (LDH) level are outlined in Table 3 . Overall, 10 of the 27 study patients (37%) responded in terms of either anemia or splenomegaly. These included 6 patients (22%) who either normalized their hemoglobin level (4 patients) or became red blood cell transfusion independent (2 patients). The remaining 4 patients displayed a minor spleen response, without an associated improvement in hemoglobin level, which lasted for 1 to 3 months. Remission in the 2 patients with minor anemia response lasted for at lease 6 months each before disease progression off therapy.
All 4 patients with a major response in anemia (i.e. normalization of hemoglobin) displayed resolution of peripheral blood leukoerythroblastosis as well as normalization of serum LDH level (Table 5 ; patients # 1, 2, 3, and 4). In addition, 2 of the 4 patients experienced a reduction in bone marrow fibrosis ( Figure 1 ) and angiogenesis (Table 5 ; patients # 1 and 2). The first of these 2 patients (Table 5 ; patient #1) with PPMM displayed a baseline del(5)(q13q33) cytogenetic abnormality as well as a heterozygous JAK2 V617F mutation. The cytogenetic abnormality became undetectable at 6 months of protocol treatment. The disappearance of del(5q) was confirmed by FISH using probes for 5p15.2 (D5S23, D5S721) and 5q31 (EGR1) with documentation of treatment-associated reduction in the percentage of abnormal nuclei from 78% to 0% (normal < 6%). Interestingly, the change in del(5q)
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From status in the particular patient was accompanied by a reduction in JAK2 V617F mutation burden (data not shown). The patient remains in remission at 3+ months after drug discontinuation. The second patient with bone marrow histological response (Table 5 ; patient #2) had AMM with normal baseline cytogenetic findings and a heterozygous JAK2 V617F mutation that was not affected by lenalidomide therapy despite continued remission at 5+ months after discontinuing protocol therapy that consisted of 3 cycles of lenalidomide. Similarly, JAK2 V617F mutational status was not affected by treatment in the third major anemia responder who had a homozygous mutation (Table 5 ; patient #4). This patient and the fourth major anemia responder (Table 5 ; patient #3) have now relapsed off therapy after 2 and 6 months of treatment discontinuation.
Interestingly, 3 of the 4 major anemia responders had antecedent polycythemia vera or essential thrombocythemia as compared to 3 of 22 without such a response (p=0.01). Similarly, the 4 treatment responders displayed significantly less bone marrow fibrosis (p = 0.002). On the other hand, neither JAK2 mutational status nor degree of bone marrow angiogenesis appeared to affect lenalidomideinduced major anemia response (p=NS). Because of the now recognized connection between lenalidomide treatment response and the presence of del(5q) in MDS, 26 we employed additional FISH analysis in all 4 major anemia responders but did not identify a cytogenetically occult del(5q) abnormality. Finally, none of the 4 major anemia responders but both patients with minor anemia response were previously exposed to thalidomide therapy.
Study 2. (MD Anderson Cancer Center) i. Patients
Forty-one patients were accrued between July 21, 2004 and July 8, 2005. Thirty-six of the 41 patients (88%) were previously treated and 13 (32%) had previous exposure to thalidomide. It is to be noted that the study at MD Anderson Cancer Center (MDACC) included patients with a hemoglobin of > 10 g/dL if they were otherwise symptomatic from either splenomegaly or thrombocytopenia.
Accordingly, pre-treatment hemoglobin level was ≤ 10 g/dL in only 19 (46%) of the 41 study patients including 13 (32%) who were red blood cell transfusion-dependent at study entry. Similarly, protocol treatment eligibility criteria at MDACC included a platelet count of ≥ 30 x 10 9 /L (Table 1) . Other baseline laboratory findings are detailed in Table 2 . Cytogenetic abnormalities were detected in 17 patients (42%). Bone marrow angiogenesis was not evaluated in the study from MDACC. Thirty-five patients have been assessed for JAK2 V617F mutation and it was identified in 18 (51%) of them.
ii. Treatment details and adverse events
The baseline platelet count dictated the starting dose for lenalidomide at MDACC; 10 mg/day if platelet count > 100 x 10 9 /L and 5 mg/day otherwise. Twenty-five (61%) and 12 patients (29%) received more than 3 or 6 cycles of therapy, respectively, depending on both drug tolerance and response assessment after 3 and 6 months of therapy (Table 1) . Neutropenia (32%) and thrombocytopenia (27%) were the major grade 3 or 4 drug side effects. On the other hand, severe nonhematologic toxicity was infrequently seen (Table 4) . Six patients (3 with PTMM, 2 with AMM, and 1 with PPMM) experienced drug-induced thrombocytosis (peak platelet count 933-1631 x 10 9 /L). Both these and other adverse events improved upon drug withdrawal. To date, 5 deaths have been reported and none were directly attributed to drug side effects. One patient died while on therapy (week 7) from non-neutropenic sepsis whereas the other four had been off therapy for 5, 15, 31, and 33 weeks, respectively, at time of death. Causes of death included cerebrovascular accident, subdural hematoma, progression into acute leukemia, and complications from allogeneic stem cell transplantation.
iii. Response to lenalidomide therapy
The median post-treatment follow up at the time of this writing was 5 months (range 1-14). To date, 21 patients (51%) remain on drug therapy. Response rates in anemia, splenomegaly, Table 3 . Ten (24%) of the 41 study patients responded in terms of anemia (2 patients), splenomegaly (6 patients), or both (2 patients). Among these, 4 (21%) of the 19 patients with a baseline hemoglobin level of < 10 g/dL, including one who was transfusion dependent, attained a major anemia response by normalizing their hemoglobin level (Table 5 ; patients # 5, 6, 7, and 8). Three of these 4 patients were negative for JAK2 V617F (Table 5; patients # 6, 7, and 8). All 4 had de novo MMM without antecedent history of either PV or ET. The spleen was palpably enlarged in 2 of these 4 patients before treatment and became impalpable in one patient (Table 5 ; patient # 6) and decreased is size from 10 cm to 2 cm in the second patient (Table 5; patient # 5), as a result of treatment. Only one of the 4 major anemia responders had a baseline cytogenetic abnormality (trisomy 9) that was not affected by treatment (Table 5 ; #5). To date, 3 of the 4 anemia responders remain in remission for 6 to 36 weeks on active therapy (Table 5 ; patients # 5, 6, and 7). The fourth patient relapsed off therapy (Table 5; 
Discussion
Among many drugs that have recently been investigated in MMM, thalidomide has displayed the best therapeutic activity in terms of anemia. 27 In one of the original studies involving single agent thalidomide therapy in MMM (n=15), oral thalidomide at an average dose of 200 mg/day was poorly tolerated but produced anemia and spleen response rates of approximately 20% and 25%, respectively. 17 A higher proportion of patients experienced an increase in platelet count. Subsequently, both lower drug doses (50 mg/day) 28 and combination of low dose thalidomide (50 mg/day) and prednisone (a tapering schedule starting at 30 mg/day) 29 were shown to be better tolerated as well as more effective in terms of anemia response. This was the primary rationale for the current phase II studies in our respective institutions that evaluated the therapeutic activity of lenalidomide, a more potent as well as less neurotoxic thalidomide analog, in MMM.
Lenalidomide is an IMiD ® , a proprietary class of thalidomide analogs that have a broad cytokine modulatory activity; inhibit TNF-α, IL-1β, IL-6, and IL-12 while they upregulate IL-2 and interferon-γ production by T helper-1 cells and IL-5 and IL-10 production by T helper-2 cells. 30 The
IMiDs co-stimulate T cells and are anti-angiogenic. Depending on the assay used, lenalidomide is estimated to be 50 to 2,000 fold more potent than thalidomide. 31, 32 Clinical treatment trials with singleagent lenalidomide have been reported in both non-hematologic 33, 34 and hematologic 26, 35 malignancies with more promising results in the latter, especially in multiple myeloma and the myelodysplastic syndrome (MDS). MDS is a clonal stem cell disease that displays some similarities with MMM in terms of both disease biology and clinical features. 36 In a recently published study, 26 43 patients with primarily low-risk MDS and symptomatic anemia were treated with either 25 or 10 mg daily doses of lenalidomide continuously or for 21 of every 28 days (i.e. syncopated). After 16 weeks of protocol treatment, response was documented in 56% of the patients including 20 patients who became transfusion independent. In addition, 75% of patients with del(5q) featured a remarkable complete hematologic and cytogenetic response. As was the case in the current study, neutropenia and thrombocytopenia were the most common adverse events with grade 3 or 4 toxicities that ranged in frequency from 59% (10 mg/day syncopated) to 77% (25 mg/day) and 53% (10 mg/day syncopated) to 54% (25 mg/day), respectively. Additional experience from a larger, multi-center phase II study led to The current study clearly establishes lenalidomide as a viable treatment option in MMM. We were most impressed by the normalization of hemoglobin in 8 of 46 patients (17%) with a baseline hemoglobin level of below 10 g/dL (3 were transfusion dependent before treatment). In particular, we were intrigued by the quality of response in 4 of these patients who also displayed resolution of leukoerythroblastosis (a hallmark of MMM). In addition, 2 of the 4 patients experienced a posttreatment reduction in bone marrow fibrosis and angiogenesis and one with del(5q) clone attained a complete cytogenetic remission that was confirmed by a more sensitive FISH technique. The particular patient remained JAK2 V617F -positive, however, despite a reduction in mutation burden (data not shown). These observations suggest that del(5q), in this instance, might be a JAK2 V617F subclone and that lenalidomide's peculiar effect on del(5q)-associated clonal myelopoiesis might be independent of the underlying histopathology. At the same time, it is evident that the drug might be active even in the absence of del(5q), as has been noted before with MDS. 26 On the other hand, the fact that 3 of the 4 major anemia responders who displayed resolution of myelophthisis had secondary myelofibrosis did not go unnoticed but the numbers were too small to draw any conclusions.
Four of the 8 patients with major anemia response were accrued to the Mayo Clinic study and accordingly received a maximum of 6 months therapy. To date, 2 of these 4 patients remain in remission after 3 and 5 months of treatment discontinuation whereas the other two relapsed off therapy. Similarly, 3 of 4 major anemia responders from the MD Anderson clinical trial who continue to receive active therapy have not relapsed after 6 to 36 weeks whereas the fourth patient has relapsed off therapy. Therefore, continued treatment might be necessary to sustain lenalidomide-induced remissions in MMM. Furthermore, the observation of a substantial reduction in serum LDH in more than two-thirds of treated patients, regardless of documented clinical response, is intriguing and its relevance within the context of a longer treatment schedule remains to be determined.
At the present time, the mechanism of hematological benefit from drug therapy in MMM is no more lucid for lenalidomide than it is for thalidomide. Regardless, as has been the case in multiple myeloma, 37 combining lenalidomide with corticosteroids carries the prospect of better response rates and such a possibility in MMM is currently being evaluated by an Eastern Cooperative Oncology Group coordinated study. In the meantime, it is important to recognize the non-trivial occurrence of severe drug-induced myelosuppression that dictates close monitoring of complete blood count during treatment. On the other hand, the current study did not disclose excess risk of thromboembolic events (only one case among all 68 study patients), an issue of potential relevance in patients with multiple myeloma receiving lenalidomide-or thalidomide-based combination chemotherapy.
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For The two patients represent patients #1 and #2 from Table 5 .
For Anemia: (patients that entered the study as transfusion dependent needed to maintain response for at least 3 months. Transfusion independent patients needed to maintain response for at least 1 month to be considered responses).
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